Recent Updates
Recently added Catalysts
SRPT Positive Sentiment

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Key Takeaway: Sarepta Therapeutics will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3. Senior management will discuss the company's advancements in precision genetic medicine for rare diseases. The presentation will be available via live webcast and archived for 90 days on their investor relations website.
Price reaction · baseline $18.12 (2026-02-23 close) · hit pre-market · 5 other SRPT headline(s) in the window, move may be shared
day 0 close · peak
+4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sarepta is a leader in precision genetic medicine.
  • The company is actively engaging with investors through presentations.
  • They have a strong focus on rare diseases, particularly Duchenne muscular dystrophy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
16.8%
average across 4 past catalysts
Lead asset
Eteplirsen
Phase 3 · Muscular Dystrophy, Duchenne

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the TD Cowen 46thAnnual Health Care Conference at the Boston Marriott Copley Place in Boston, Mass. on Tuesday, March 3 at 1:50 p.m. E.T.
The presentations will be webcast live under the investor relations section of Sarepta’s website athttps://investorrelations.sarepta.com/events-presentationsand will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta TherapeuticsSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.

Frequently Asked Questions

When will Sarepta present at the TD Cowen Conference?

Sarepta will present on March 3 at 1:50 p.m. E.T.

Where can I watch the Sarepta presentation?

The presentation will be webcast live on Sarepta's investor relations website.

What is Sarepta's focus in medicine?

Sarepta focuses on precision genetic medicine for rare diseases.

How long will the presentation be archived?

The presentation will be archived for 90 days after the event.

Last updated: Feb 24, 2026